Jen-Yu Amy Chang

Jen-Yu Amy Chang

Auto-generated profile, based on publicly available information

Jen-Yu Amy Chang

Lumanity, Sheffield, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HLHsiang-Wen Lin
Hsiang-Wen Lin
CLChia-Ing Li
Chia-Ing Li
FLFang-Ju Lin
Fang-Ju Lin
JCJen-Yu Chang
Jen-Yu Chang
CGChurn-Shiouh Gau
Churn-Shiouh Gau
CHChien-Ning Hsu
Chien-Ning Hsu
To date, a value set for the EQ-5D-5L based on the health state preferences of the general Taiwanese population has not been available. This study aimed to develop a Taiwanese value set for EQ-5D-5L to facilitate health technology assessment for medical products and services. An international standardized protocol for EQ-5D-5L valuation studies developed by the EuroQol group was adopted. Adult members of the general public were recruited from six geographic regions in Taiwan. In computer-based face-to-face interviews, each participant completed 10 composite time trade-off (C-TTO) tasks and 7 discrete choice experiment (DCE) tasks. The C-TTO and DCE data were modeled alone or in combination (using hybrid models) with additive models containing 20 dummy variables as main effects. The model performance was assessed both quantitatively and qualitatively (mainly logical consistency and prediction patterns). Of 1,073 recruited participants, 1,000 completed the study. Approximately 13% of observed utility values were -1 in the C-TTO tasks. The hybrid model, using all available data that assumed C-TTO response values left-censored at -1 and with main effects coefficients with logical consistency (monotonicity), was considered as the most appropriate model. The predicted utility ranged from -1.0259 to 1. An EQ-5D-5L value set was developed for Taiwan using an established study protocol and a representative sample of the general population. This may facilitate health economic evaluations and decision making on resource allocation under Taiwan’s national health insurance program in the future.

16 July 2019 in Journal of Women's Health
Verified
Journal Article
Closed access
HCHsun-Jung Chan
Hsun-Jung Chan
JCJen-Yu Chang
Jen-Yu Chang
SESteven R. Erickson
Steven R. Erickson
CWChi-Chuan Wang
Chi-Chuan Wang
Background: The issue of suboptimal influenza vaccination coverage among pregnant women remains relevant. Our study aimed to explore the determinants and coverage of influenza vaccination among pregnant women in the United States using a nationally representative sample. Materials and Methods: This study was conducted with the 2012–2016 U.S. National Health Interview Survey. The Andersen's Health Behavior Model was applied as the conceptual framework to explore potential factors that may influence the influenza vaccination rate. A series of individual determinants, categorized into predisposing, enabling, and need factors, were compared using logistic regressions between women who received an influenza vaccination before or during pregnancy and those who did not. Results: An average of 36% women received an influenza vaccination before or during pregnancy among an estimated five million pregnant women. Even though the percentage increased from 31% in 2012 to 40% in 2016, it remained lower than the Healthy People 2020 target of 80%. The odds of receiving an influenza vaccination before or during pregnancy were lower among women who had public or no insurance coverage (odds ratio [OR]; 95% confidence interval, 0.510 [0.323–0.806] and 0.351 [0.175–0.705], respectively), lived in South (0.546 [0.336–0.887]), ever smoked 100 cigarettes (0.622 [0.419–0.923]), and had infrequent to light alcohol consumption in the past year (0.670 [0.457–0.983], reference: no alcohol consumption in the past year). Having a bachelor's degree increased the odds of getting an influenza vaccine compared to a high school diploma or less (2.086 [1.353–3.215]). Conclusions: Our study found that the influenza vaccination coverage among pregnant women remains suboptimal, and disparities may still exist across women with different sociodemographic and socioeconomic status. Clinicians should actively recommend influenza vaccination for pregnant women, and policy makers may consider developing interventions to improve the vaccination rate.

22 August 2017 in International Journal for Quality in Health Care
Verified
Journal Article
Open access
PDF file
JCJen-Yu Chang
Jen-Yu Chang
CWChi-Chuan Wang
Chi-Chuan Wang
HKHao-Cheng Kang
Hao-Cheng Kang
LSLi-Jiuan Shen
Li-Jiuan Shen
CHChih-Fen Huang
Chih-Fen Huang
To investigate the cost-effectiveness of the first patient self-paying pharmacist-assisted warfarin monitoring (PAWM) program in Taiwan. A Markov model with a 1-month cycle length and a 20-year time horizon was employed in this study. The model is composed of the following eight states: three no-event states (i.e. ‘subtherapeutic,’ ‘within therapeutic’ and ‘supratherapeutic’ states), two serious adverse events (AEs) (i.e. bleeding and thromboembolism), two sequelae states and death. The likelihood of events, costs and utilities were derived from local databases and literature, if applicable. This study was conducted with a payer's perspective and all costs were discounted with a rate of 3%. A pharmacist-led clinic. A hypothetical cohort of 10 000 participants. PAWM versus usual care. Average quality-adjusted life-years (QALYs) gained and cost increments per patient, and incremental cost-effectiveness ratios (ICERs). The PAWM program resulted in an average of 0.13 QALYs gained and a cost increment of NT$53 850 (US$1683) per patient. As the ICER (NT$410 749 [US$12 836]) was less than the gross domestic product per capita (NT$631 142 [US$19 723]), the PAWM was considered to be very cost-effective. The sensitivity analyses suggested that our result was robust and that the PAWM program had an 86% probability of being very cost-effective. Even if the costs saved from avoiding AEs were thought to be minimal due to the low-medical expenditures in Taiwan, the PAWM program was demonstrated to be economical. According to our findings, the policymakers should consider reimbursing such a service.

1 April 2024 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
JCJen-Yu Amy Chang
Jen-Yu Amy Chang
JCJames B. Chilcott
James B. Chilcott
NLNicholas R. Latimer
Nicholas R. Latimer


1 August 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
CHConor Hickey
Conor Hickey
MSMatthew F Sidovar
Matthew F Sidovar
AGAndrea Garcia
Andrea Garcia
KKKen Kramer
Ken Kramer
JCJen-Yu Amy Chang
Jen-Yu Amy Chang
ACAndrew J Cutler
Andrew J Cutler
Aim: The recently approved first-in-class combination therapy xanomeline/trospium chloride (KarXT) demonstrated superiority over placebo in three randomized controlled trials (RCTs) of adults with schizophrenia. This analysis investigates its relative efficacy, safety and tolerability compared with eight second-generation antipsychotics for the acute treatment of schizophrenia via network meta-analyses (NMAs). Materials & methods: A 2019 systematic literature review was adapted and updated to identify RCTs of eight antipsychotics in adults with schizophrenia. NMAs were conducted to compare KarXT against these antipsychotics for 11 endpoints of interest, measured at 4–6 weeks, covering efficacy (Positive and Negative Syndrome Scale [PANSS]; Clinical Global Impressions – Severity [CGI-S]), safety (weight change, sedation and somnolence) and tolerability (discontinuation; all-cause and due to adverse events). Results: A network of 49 RCTs including 14,680 patients was formed. KarXT was associated with greater odds of clinical response (≥30% improvement in PANSS total score) than aripiprazole (odds ratio [OR]: 1.85; 95% credible interval [CrI]: 1.11, 3.11), brexpiprazole (OR: 2.23; 95% CrI: 1.34, 3.83) and cariprazine (OR: 2.05; 95% CrI: 1.19, 3.57); improved change from baseline (CFB) PANSS positive symptoms score versus brexpiprazole; improved CFB CGI-S score against aripiprazole, brexpiprazole, cariprazine and olanzapine; reduced odds of clinically significant (≥7%) weight gain over all comparators except clozapine (no data); improved CFB weight against brexpiprazole, clozapine, olanzapine, quetiapine and risperidone; and greater odds of all-cause discontinuation than aripiprazole, brexpiprazole, clozapine, lumateperone, olanzapine, quetiapine and risperidone. Conclusion: In this NMA, for patients receiving acute treatment for schizophrenia, KarXT compared favorably with second-generation antipsychotics on key efficacy endpoints and in terms of unwanted weight gain.